Bristol Myers Squibb (BMY) Non-Current Deffered Revenue (2009 - 2019)
Bristol Myers Squibb (BMY) reported Non-Current Deffered Revenue of $448.0 million for Q1 2019, little changed year-over-year from $447.0 million in Q1 2018, and down 4.27% on a QoQ basis from $468.0 million in Q4 2018.
Bristol Myers Squibb (BMY) has 11 years of Non-Current Deffered Revenue data on file, last reported at $448.0 million in Q1 2019.
- Quarterly Non-Current Deffered Revenue changed 0.22% year-over-year to $448.0 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $448.0 million (changed 0.22% YoY) and the FY2018 annual result came in at $468.0 million, up 3.08% from the prior year.
- Non-Current Deffered Revenue slipped to $448.0 million in Q1 2019 per BMY's latest filing, from $468.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $697.0 million in Q1 2015 and bottomed at $447.0 million in Q1 2018.
- The 5-year median for Non-Current Deffered Revenue is $528.0 million (2017), against an average of $542.5 million.
- The widest annual swing landed in 2015, when Non-Current Deffered Revenue tumbled 35.99%; it then grew 3.08% in 2018.
- Tracing BMY's Non-Current Deffered Revenue over 5 years: stood at $586.0 million in 2015, then slipped by 6.66% to $547.0 million in 2016, then decreased by 17.0% to $454.0 million in 2017, then grew by 3.08% to $468.0 million in 2018, then decreased by 4.27% to $448.0 million in 2019.
- Per Business Quant, the three latest BMY Non-Current Deffered Revenue figures stand at $448.0 million (Q1 2019), $468.0 million (Q4 2018), and $486.0 million (Q3 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 448.00 Mn |
| Dec 31, 2018 | 468.00 Mn |
| Sep 30, 2018 | 486.00 Mn |
| Jun 30, 2018 | 501.00 Mn |
| Mar 31, 2018 | 447.00 Mn |
| Dec 31, 2017 | 454.00 Mn |
| Sep 30, 2017 | 492.00 Mn |
| Jun 30, 2017 | 512.00 Mn |
| Mar 31, 2017 | 528.00 Mn |
| Dec 31, 2016 | 547.00 Mn |
| Sep 30, 2016 | 567.00 Mn |
| Jun 30, 2016 | 586.00 Mn |
| Mar 31, 2016 | 606.00 Mn |
| Dec 31, 2015 | 586.00 Mn |
| Sep 30, 2015 | 630.00 Mn |
| Jun 30, 2015 | 667.00 Mn |
| Mar 31, 2015 | 697.00 Mn |
| Dec 31, 2014 | 770.00 Mn |
| Sep 30, 2014 | 810.00 Mn |
| Jun 30, 2014 | 1.04 Bn |
| Mar 31, 2014 | 1.06 Bn |
| Dec 31, 2013 | 769.00 Mn |
| Sep 30, 2013 | 4.20 Bn |
| Jun 30, 2013 | 4.15 Bn |
| Mar 31, 2013 | 4.10 Bn |
| Dec 31, 2012 | 4.02 Bn |
| Sep 30, 2012 | 4.01 Bn |
| Jun 30, 2012 | 805.00 Mn |
| Mar 31, 2012 | 836.00 Mn |
| Dec 31, 2011 | 866.00 Mn |
| Sep 30, 2011 | 860.00 Mn |
| Jun 30, 2011 | 923.00 Mn |
| Mar 31, 2011 | 899.00 Mn |
| Dec 31, 2010 | 895.00 Mn |
| Dec 31, 2009 | 949.00 Mn |
| Sep 30, 2009 | 934.00 Mn |
| Jun 30, 2009 | 872.00 Mn |